long intergenic non-protein coding RNA 2223Genealiases: []
Q-omics provides the consensus-scored LINC02223 profile across patient tissues and cancer cell-line models. LINC02223 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, LINC02223 is differentially expressed in 12, with the highest sampling consensus in COAD. Additionally, LINC02223 RNA expression shows 8,609 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight BRCA, COAD, and PDAC as cancer lineages where LINC02223 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC02223 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC02223 survival associations across molecular data types. LINC02223 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC02223 RNA expression–survival associations across cancer types. High LINC02223 expression shows unfavorable associations in BRCA, CESC, OV, KIRC and SKCM, but favorable associations in MESO. The BRCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BRCA as the clearest survival context for LINC02223 RNA expression.
This table summarizes LINC02223 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for LINC02223. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC02223 shows higher tumor expression in COAD, LUSC, KICH, LUAD, HNSC and BRCA. The COAD box plot shows higher LINC02223 RNA expression in tumor versus normal tissue (log2 FC = +0.456, t-test p < 0.001).
This table shows molecular features associated with LINC02223 in patient tissues and cancer cell lines. In patient samples, LINC02223 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set.
